219 related articles for article (PubMed ID: 28332450)
21. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
22. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
24. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Carollo A; Papi S; Grana CM; Mansi L; Chinol M
Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
[TBL] [Abstract][Full Text] [Related]
25. Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.
Gauthé M; Lièvre A; Alberini JL
Clin Nucl Med; 2015 Nov; 40(11):e516-7. PubMed ID: 26204216
[TBL] [Abstract][Full Text] [Related]
26. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
27. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
[TBL] [Abstract][Full Text] [Related]
28. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
29. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
30. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
31. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.
Ambrosini V; Nanni C; Fanti S
PET Clin; 2014 Jul; 9(3):323-9. PubMed ID: 25030395
[TBL] [Abstract][Full Text] [Related]
32. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
34. [68Ga-DOTA-PET for neuroendocrine tumours].
Loimaala A; Mäenpää H; Lipponen T; Schildt J; Kämäräinen EL; Karhumäki L; Ahonen A
Duodecim; 2014; 130(19):1931-8. PubMed ID: 25558614
[TBL] [Abstract][Full Text] [Related]
35. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
Papadakis GZ; Karantanas AH; Marias K; Millo C
Eur J Radiol; 2021 Oct; 143():109932. PubMed ID: 34482177
[TBL] [Abstract][Full Text] [Related]
36. Imaging of NETs with PET radiopharmaceuticals.
Ambrosini V; Tomassetti P; Franchi R; Fanti S
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
[TBL] [Abstract][Full Text] [Related]
37. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
38. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors?
Cuccurullo V; Faggiano A; Scialpi M; Cascini GL; Piunno A; Catalano O; Colao A; Mansi L
Minerva Endocrinol; 2012 Dec; 37(4):367-77. PubMed ID: 23235192
[TBL] [Abstract][Full Text] [Related]
39. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
[TBL] [Abstract][Full Text] [Related]
40. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
